Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate vTv Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding vTv Therapeutics Inc.’s stock price such as:

• vTv Therapeutics Inc.’s current stock price and volume
• Why vTv Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for VTVT from analysts
• VTVT’s stock price momentum as measured by its relative strength

About vTv Therapeutics Inc. (VTVT)

Before we jump into vTv Therapeutics Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Want to learn more about vTv Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about vTv Therapeutics Inc..

vTv Therapeutics Inc.’s Stock Price as of Market Close

As of March 13, 2026, 4:00 PM, CST, vTv Therapeutics Inc.’s stock price was $33.280.

vTv Therapeutics Inc. is down 1.28% from its previous closing price of $33.710.

During the last market session, vTv Therapeutics Inc.’s stock traded between $31.210 and $37.150. Currently, there are approximately 12.45 million shares outstanding for vTv Therapeutics Inc..

vTv Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

vTv Therapeutics Inc. Stock Price History

vTv Therapeutics Inc.’s (VTVT) price is currently down 12.79% so far this month.

During the month of March, vTv Therapeutics Inc.’s stock price has reached a high of $38.960 and a low of $31.210.

Over the last year, vTv Therapeutics Inc. has hit prices as high as $44.000 and as low as $14.000. Year to date, vTv Therapeutics Inc.’s stock is down 16.78%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused vTv Therapeutics Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 13, 2026, there were 0 analysts who downgraded vTv Therapeutics Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate vTv Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on vTv Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about vTv Therapeutics Inc. (VTVT) by visiting AAII Stock Evaluator.

Relative Price Strength of vTv Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 13, 2026, vTv Therapeutics Inc. has a weighted four-quarter relative price strength of 11.50%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how vTv Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

vTv Therapeutics Inc. Stock Price: Bottom Line

As of March 13, 2026, vTv Therapeutics Inc.’s stock price is $33.280, which is down 1.28% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like vTv Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.